Navigation Links
Zamansky & Associates LLC Investigates Affymax Inc. Over Its Recall of Omontys Due to Fatal Reactions
Date:2/26/2013

New York, New York (PRWEB) February 26, 2013

Zamansky & Associates LLC notifies all investors in Affymax Inc. (“Affymax”) that it is investigating the recall of Omontys, its anemia treatment for kidney dialysis patients due to reports of fatal reactions. On February 25, 2012, according to Bloomberg News, Affymax’s stock price fell as much as 87 percent after the recall to $2.97 per share, after it had gained 61 percent over the previous 12 months. This investigation concerns potential securities fraud or disclosure violations by Affymax, and its officers and directors, for disclosure failures relating to the fatal reactions which caused the recall.

According to the Notice issued to healthcare providers by Affymax and its marketing partner, the “use of OMONTYS may result in serious hypersensitivity reactions including anaphylaxis, which may be life-threatening or fatal,” and “to date, fatal reactions have been reported in approximately 0.02% of patients following the first dose of intravenous administration.” Reuters reported that the U.S. Food and Drug Administration on Sunday alerted healthcare providers about the recall, and said it had received 19 reports of anaphylaxis from dialysis centers in the United States.

The investigation by Zamansky & Associates LLC concerns whether Affymax knew and failed to disclose the frequency and/or severity of these reactions to Omontys, and the FDA’s response, while its stock price rose over the last year. “If Affymax’s officers and directors knew that its stock price was artificially inflated, and would likely collapse when this news was released to the market, then there was securities fraud or a disclosure law violation,” according to Jake Zamansky.

What Affymax Investors Can Do

If you are a shareholder of Affymax and would like to discuss your legal rights, you may, without obligation or cost to you, email jake (at) zamansky (dot) com or call the law firm at (212) 742-1414.

About Zamansky & Associates

Zamansky & Associates LLC is one of the leading law firms specializing in securities fraud and financial services arbitration and class action litigation. We represent both individual and institutional investors. Our practice is nationally recognized for our ability to aggressively prosecute cases and recover losses.

To learn more about Zamansky, please visit our website, http://www.zamansky.com.

Contacts

Zamansky & Associates, LLC
50 Broadway - 32nd Floor
New York, NY 10004
Jake Zamansky, 212-742-1414
jake(at)zamansky(dot)com

Read the full story at http://www.prweb.com/releases/2013/2/prweb10467316.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Michigan’s Exotic Automation & Supply to Exhibit at the 2013 Work Truck Show & Green Truck Summit
2. Parents Recommend Americord over CBR & Viacord
3. Testing Positive for Stability & Growth - Research Report on CombiMatrix Corporation, Cepheid, PerkinElmer, Inc., Life Technologies Corp. and Laboratory Corp. of America Holdings
4. R&D, Innovation Key to Success - Research Report on Varian Medical Systems, Inc., Boston Scientific Corporation, Stryker Corporation, St. Jude Medical, Inc., and Thermo Fischer Scientific Inc.
5. DuPont Tate & Lyle Bio Products Announces Winner of Zemea® Innovation Award
6. Industry Thought Leader to Present Transformational Opportunities for Industry Adoption of Advanced Analytics at 2013 HIMSS Annual Conference & Exhibition
7. Global Biopesticides Market Trends & Forecasts (2012 – 2017)
8. Neurovascular/Interventional Neurology Market: Global Trends & Competitive Analysis - 2017
9. Corporate Financial Planning Experts Gather at IE – Innovation Enterprise’s Financial Planning & Analysis for Pharma & Biotech Summit
10. Foot & Ankle Devices Market (2012 – 2017) By Product Type (External Fixation, Internal Fixation, Joint Replacement, Prosthesis, Bracing) - Global Trends & Competitive Analysis
11. The Leukemia & Lymphoma Society: Impacting Blood Cancers and Beyond
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Regular discussions on a range of subjects ... the two entities said Poloz. Speaking at a ... , he pointed to the country,s inflation target, which ... "In certain areas ... have common economic goals, why not sit down and address ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS ... the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, ... proud to add Target to its list of well-respected retailers. This list includes ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
(Date:6/23/2016)... ... 23, 2016 , ... STACS DNA Inc., the sample tracking software company, today ... Laboratory, has joined STACS DNA as a Field Application Specialist. , “I am ... and COO of STACS DNA. “In further expanding our capacity as a scientific integrator, ...
Breaking Biology Technology:
(Date:5/16/2016)... 16, 2016   EyeLock LLC , a market ... opening of an IoT Center of Excellence in ... the development of embedded iris biometric applications. ... convenience and security with unmatched biometric accuracy, making it ... from DNA. EyeLock,s platform uses video technology to deliver ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
Breaking Biology News(10 mins):